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Women of African ancestry present with more advanced ovarian tumors and have lower 
five-year survival than Caucasian women.  Progress in determining risk factors 
contributing to those differences in ovarian cancer development and mortality is 
hampered by the dearth of research.  This study shows novel associations of genetic 
variants from EGFR and UGT2A1/2 gene regions with ovarian cancer in African 
Americans that is suggestive of proliferation and tobacco metabolism pathway 
alterations that contribute to health disparities.  
 
ACKNOWLEDGMENTS 
The BEL study would like to thank Gilian Peuteman, Thomas Van Brussel, Annick Van 
den Broeck and Joke De Roover for technical assistance. The CAM study was 
supported by Cancer Research UK, the University of Cambridge, and the National 
Institute for Health Research Cambridge Biomedical Research Centre. The MOF study 
would like to thank the Total Cancer Care™ Protocol and the Collaborative Data 
Services and Tissue Core Facilities at the H. Lee Moffitt Cancer Center & Research 
Institute, an NCI designated Comprehensive Cancer Center, Merck Pharmaceuticals 
and the state of Florida (MOF). The NHS/NHSII studies thank the following state cancer 
registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, 
ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, 
and WY. The SEA study thanks the SEARCH team, Craig Luccarini, Caroline Baynes, 
Don Conroy. The UKO study thanks I. Jacobs, M. Widschwendter, E. Wozniak, A. 
Ryan, J. Ford and N. Balogun for their contribution to the study. The WMH study thanks 
the Gynaecological Oncology Biobank at Westmead, a member of the Australasian 
Biospecimen Network-Oncology group.  
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
 
DR. DELORES  GRANT (Orcid ID : 0000-0001-8981-8930) 
DR. JILL  BARNHOLTZ-SLOAN (Orcid ID : 0000-0001-6190-9304) 
DR. KIRSTEN  MOYSICH (Orcid ID : 0000-0002-4678-2058) 
DR. JENNIFER  PERMUTH (Orcid ID : 0000-0002-4726-9264) 
DR. DANIEL W CRAMER (Orcid ID : 0000-0002-8024-3066) 
 
 
Article type      : Original Research 
 
 
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and 
EGFR polymorphisms associated with epithelial ovarian cancer in African American 
Women 
 
RUNNING TITLE: Genetic association with variants in the vitamin D pathway 
 
KEYWORDS: ovarian cancer, genetic association, vitamin D pathway, African ancestry risk 
 
 
WORD COUNT: 2,885 
NUMBER OF TABLES: 2 
NUMBER OF SUPPLEMENTAL TABLES: 8 
NUMBER OF FIGURES: 0 
 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
CONFLICT OF INTEREST: The authors have no conflicts of interest to disclose. 
 
NOVELTY & IMPACT STATEMENTS 
Women of African ancestry present with more advanced ovarian tumors and have lower 
five-year survival than Caucasian women.  Progress in determining risk factors 
contributing to those differences in ovarian cancer development and mortality is 
hampered by the dearth of research.  This study shows novel associations of genetic 
variants from EGFR and UGT2A1/2 gene regions with ovarian cancer in African 
Americans that is suggestive of proliferation and tobacco metabolism pathway 
alterations that contribute to health disparities.  
 
 
ABSTRACT 
An association between genetic variants in the vitamin D receptor (VDR) gene and 
epithelial ovarian cancer (EOC) was previously reported in women of African ancestry 
(AA).  We sought to examine associations in VDR and additional genes from vitamin D 
biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, 
CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using 
the custom-designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 
Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high-grade serous 
(HGSOC), and 1,235 controls.  All subjects are of African ancestry (AA).  Logistic 
regression was performed to estimate odds ratios (OR) and 95% confidence intervals 
(CI). We further evaluated statistical significance of selected SNPs using the Bayesian 
False Discovery Probability (BFDP). A significant association with EOC was identified in 
the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = (1.2, 1.7) 
p=1.2 x 10-6, BFDP=0.02); and an association with HGSOC was identified in the EGFR 
region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = (1.6, 3.4) p=1.6 x 10-5, 
BFDP=0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% 
CI = (1.2, 1.7) p=2.3 x 10-5, BFDP=0.23).  Genetic variants in the EGFR and UGT2A1/2 
may increase susceptibility of EOC in AA women. Future studies to validate these 
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findings are warranted.  Alterations in EGFR and UGT2A1/2 could perturb enzyme 
efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.   
 
 
 
INTRODUCTION 
Women of African ancestry (AA) have the lowest incidence of ovarian cancer 
worldwide, but they tend to present with more advanced tumors and have lower five-
year survival (35%) compared to women of European descent (47%) in nearly every 
cancer subtype 1, 2. Compared to Caucasian women, there have been fewer published 
studies investigating the association between common risk factors, such as tubal 
ligation, use of hormonal contraceptives, obesity, body powder and dietary patterns, and 
ovarian cancer risk in AA 1, 3-9. Moreover, the investigation of genetic susceptibility to 
epithelial ovarian cancer (EOC) in AA has not been comprehensive. The limited 
assessment of genetic susceptibility among AA are in modest sized study populations of 
candidate genes including the repeat polymorphisms of the androgen receptor (AR), 
vitamin D receptor (VDR) and cellular transport genes, where an association with risk of 
ovarian cancer was observed 10-12.  
The vitamin D receptor mediates the regulation of a pleotropic cascade of 
physiological responses; including those involved in phase I and phase II detoxification 
and the epidermal growth factor receptor (EGFR) proliferation pathways in ovarian and 
other cancer cell lines; through VDR/DNA interactions and bioavailability of vitamin D 13-
17
.  A VDR variant, rs7305032, was associated with ovarian cancer in 125 cases and 
155 controls of AA but other observations were limited because of small sample size 11.  
Moreover, known genetic varations in the VDR/vitamin D biosynthesis and pathway 
target genes have been implicated in AA disease risk. Therefore an objective of this 
study was assess those variants in ovarian cancer in women of African ancestry in a 
large sample.  
Using a candidate gene approach, SNPs were selected from genes involved in 
vitamin D biosynthesis and metabolism; and putative targets of VDR regulation.  Genes 
of the vitamin D biosynthesis pathways included cytochrome P450s: CYP2R1, 
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CYP27B1, CYP24A1, CYP11A1, and group-specific component-Vitamin D-binding 
protein (GC) which collectively are responsible for the homeostatic control and 
bioavailability of vitamin D 18-23.  The candidate genes involved in vitamin D metabolic 
processes included CYP3A4/5 and UDP-glucuronosyltransferase 1A  (UGT1A) locus 
members responsible for glucuronidation and hydroxylation of the biologically active and 
circulatory forms of vitamin D.  These genes are also inclusive of candidates regulated 
by vitamin D/VDR binding which included CYP3A4/5, UGT1A locus members, EGFR 
and UDP-glucuronosyltransferase 2 (UGT2) locus members; and associated, in part, 
with other cancers in AA individuals 24-39.  Thus, variants in VDR and additional genes 
from vitamin D biosynthesis and pathway targets are viable candidates to investigate 
the genetic underpinnings of ovarian cancer risk in women of African descent.   
In this study, SNPs from 11 gene regions: VDR, EGFR, UGT1A, UGT2A1/2, 
UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC, were 
genotyped, imputed then assessed for risk of EOC and high grade serous ovarian 
cancer (HGSOC) in cases and controls of AA from the African American Cancer 
Epidemiology Study (AACES) 40 and the Ovarian Cancer Association Consortium 
(OCAC) 41.   
MATERIALS AND METHODS 
Study Populations 
The Genetic Associations and Mechanisms in Oncology (GAME-ON) project comprised 
63, mostly, case-control studies from four continents (North America, Europe, Asia and 
Australia). Only 32 studies contributed subjects of African Ancestry, including AACES 
and studies in OCAC, and were included in the current analysis (Supplemental Table 1).  
AACES, previously described elsewhere 40, is a multi-center population-based case-
control study of newly diagnosed invasive EOC in African American women that 
enrolled study subjects between 2010 and 2015. Established in 2005, OCAC is an 
international consortium focused on genetic association and pooled risk factor analyses. 
The current analyses included 1,990 samples: 1,235 controls and 755 invasive EOC 
cases who passed quality control filters, all of whom were AA. The majority of the EOC 
cases were HGSOC (n= 537, 71%), followed by 49 mucionous cases (7%), 28 
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endometrioid cases (4%), 23 clear cell cases (3%), 12 mixed histology (2%) and 53 
other (7%). All subjects included in this analysis provided written informed consent as 
well as data and blood samples under ethically approved protocols. 
Genotyping, ancestry analysis and quality control 
Genotyping of AA women from OCAC was completed using the custom-designed 
533,631 SNP array, the Illumina OncoArray. Sample level quality control included 
restriction to females, filter on call rate > 95%, heterozygosity (either too big or too 
small), removal of ineligible samples, and relationship inference to check for unexpected 
first degree relatives. SNP level quality control included filter on call rate > 95%, and 
Hardy-Weinberg Equilibrium p-value > 1x10-5. After applying these procedures, 471,780 
SNPs remained. 
 Intercontinental ancestry was calculated for the OCAC and AACES samples 
using the software package FastPop 42 that was developed specifically for the 
OncoArray Consortium. Only the African ancestry samples defined as having >50% AA 
were used for the present analyses reported here. Seventy-seven cases and 120 
controls were omitted due to African ancestry <50% and one gender mismatch.  
Principal components computed using FastPop were further used to adjust for 
population structure in our analyses. 
Genotype Imputation Analysis 
Using the genotyped SNPs that passed quality control, haplotypes were phased using 
SHAPEIT v2 followed by imputation to the 1,000 Genomes Phase 3 v5 reference set 
using Minimac3.   
Gene Region and SNP Selection 
Eleven gene regions were defined based on human genome build 37. SNPs within the 
selected regions were filtered on imputation quality score (minimac imputation R-
squared) > 0.5 for imputed SNPs, or Hardy-Weinberg Equilibrium p-value > 1.0 x 10-5 
for genotyped SNPs. Quantile-quantile plots on the EOC and HGSOC dataset 
(Manichaikul et al., unpublished) have lambdas of 1.01 each within normal range 43.  
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The imputation quality scores for significant SNPs are provided.  We further applied 
filter on effective heterozygosity count > 30.  After applying filters, the following numbers 
of SNPs were remaining in each of the selected gene regions for EOC: 288 in VDR, 433 
in UGT2A1/2, 6302 in UGT2B, 919 in UGT1A, 963 in EGFR, 17 in CYP2R1, 4 in 
CYP27B1, 113 in CYP24A1, 90 in CYP11A1, 411 in CYP3A4/5 and 296 in GC.  For 
selected regions for HGSOC analysis, the number of SNPs were:  234 in VDR, 413 in 
UGT2A1/2, 5674 in UGT2B, 833 in UGT1A, 824 in EGFR, 15 in CYP2R1, 4 in 
CYP27B1, 106 in CYP24A1, 82 in CYP11A1, 375 in CYP3A4/5 and 282 in GC. 
Statistical Analysis 
Genetic association testing was carried out with adjustment for two principal 
components (PCs) of ancestry using a logistic regression model that accounts for 
genotype uncertainty under a score test as implemented in SNPTEST v2.5.2 to 
estimate odds ratios (OR) and 95 % confidence intervals (CI). For each gene region, we 
applied a gene-specific Bonferroni-threshold for statistical significance defined as 0.05 / 
number of SNPs examined for that gene. We further assessed the main results with an 
alternative to the Bonferroni threshold using the Bayesian False Discovery Probability 
(BFDP) which provides the posterior probability of a false discovery based on a given 
prior probability of non-null association at a given SNP 44. For this study we specified a 
prior probability of association at each SNP under investigation based on the total 
number of SNPs within each candidate gene region as 0.5 x 1/(NSNP / 3) where NSNP 
represents the number of SNPs in the given candidate gene region. We considered 
NSNP/3 to be an approximation of the effective number of independent SNPs within in 
each gene region, taking into account the fact that many SNPs will be correlated due to 
linkage disequilibrium. Accordingly, the specified prior indicates a 50% chance of true 
discovery within each gene region, with the prior probability of non-null association 
distributed randomly among all SNPs within the region.  In order to avoid spurious 
positive associations, we applied a filter on effective heterozygosity count (HC) > 30 in 
each of cases and controls. Here, HC is defined as N x MAF x (1-MAF) for each SNP, N 
represents the sample size (either the number of cases or the number of controls), and 
MAF represents the SNP minor allele frequency. Based on 755 EOC cases and 537 
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HGSOC cases, respectively, applying this filter equates to applying a SNP MAF filter of 
4.2% and 6% in analysis of EOC and HGSOC, respectively.  Statistical power 
calculations for AA study participants and Caucasians are included in Supplemental 
Tables 2 and 3. 
 
 RESULTS 
VDR Pathway Gene Regions and risk of EOC 
SNPs from eleven gene regions (CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, 
CYP11A1, EGFR, GC, UGT1A, UGT2A1/2, UGT2B and VDR) from VDR biosynthesis 
and pathway targets were assessed for association with EOC (Supplemental Table 4).  
The top associations are reported in table 1. Individuals carrying the major allele of SNP 
rs10017134 of the UGT2A1/2 gene region had an increased odds of EOC when 
corrected for multiple comparisons (OR=1.4, 95% CI=(1.2, 1.7), p=1.2x10-6).  The BFDP 
for rs10017134 of 0.020 corresponds to 98% posterior probability of non-null 
association for this SNP. Significant associations with EOC were also observed for 
UGT2A1/2 SNPs, rs2288741 and rs11939884.  The variants are found in both UGT2A1 
and UGT2A2 as the genes share common exons 2 through 6 45.  Supplemental Table 5 
summarizies other notable (p<0.01) SNP associations with EOC in the OncoArray 
analysis. 
 
VDR Pathway Gene Regions and risk of HGSOC 
SNPs from the ten gene regions from VDR biosynthesis and pathway targets 
were assessed for association with HGSOC (Supplemental Table 4).  The top 
associations are in reported in table 2. Individuals carrying the minor allele of EGFR 
SNP rs114972508 had more than two-fold increased odds of HGSOC (OR=2.3, 95% 
CI=(1.2, 3.4), p=1.6x10-5) (Table 2).  The posterior BFDP is 29% for SNP rs114972508 
corresponds to 71% posterior probability of non-null association.  SNP rs10017134 of 
the UGT2A1/2 gene region also showed association with HGSOC (OR=1.4, 95% 
CI=(1.2, 1.7), p=2.3x10-5) (Table 2).  The posterior BFDP is 22.8%.  Supplemental 
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Table 6 summarizies other notable (p<0.01) SNP associations with HGSOC in the 
OncoArray analysis.   
 
DISCUSSION 
 Few studies have investigated the genetic susceptibility for ovarian cancer 
among women of African descent. The assessment of candidate SNPs from 
chromosomal regions that contain genes regulated by VDR activity provides some 
evidence of association with EOC risk. The notable findings from this analysis show, for 
the first time, that risk assessments of variants in the UGT2A1/2 and EGFR gene 
regions are suggestive of associations with EOC and HGSOC. The results also 
demonstrate evidence of associations for other SNPs from the candidate gene regions 
with EOC and HGSOC. Although the candidate SNPs are located in intronic regions 
there is ample evidence that many gene regulatory regions are present in those regions 
including encoded microRNAs, alternate splice sites, and cis-regulatory modules and 
transcription factors binding sites 46-48. In addition, recent studies have shown using 
targeted RNAseq analysis that there are numerous splice variants of the UGT genes 49. 
 The UGT2A1 and 2A2 genes are distinguished by unique first exons joined to 
common exons 2–6 and are located downstream of UGT2B4 on chromosome 4 45.  
UGT2A transcripts have been detected in several extrahepatic tissues such as the lung, 
trachea, larynx, intestine, pancreas and kidney 50. UGT2A1 is an extrahepatic enzyme 
that is expressed mainly in the nasal epithelium, catalyzing the glucuronidation of 
testosterone and epitestosterone at considerable rates and has similar kinetics as the 
UGT2B gene family members 51.  There are reports that this enzyme also has activity 
toward estrogen metabolites epiestradiol and β-estradiol 52.  UGT2A1 has exhibited 
highest expression in the lung, followed by trachea, tonsil, larynx, colon, olfactory 53. 
UGT2A2 mRNA expression was reported in fetal and adult nasal mucosa tissues 54.  
However, unlike UGT2A1, other expression analyses suggested that wild-type UGT2A2 
had the highest expression in the breast, followed by trachea, larynx, and kidney 55.  
      Neither the UGT2A1 gene, nor UGT2A2 expression have been examined in ovarian 
tissue.  However, VDR ChIPseq peak locations have been identified 430 kb 
downstream of the UGT2A1/2 locus in experiments with THP-1 cells treated with 
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1a,25(OH)2D3, the biologically active form of the vitamin D hormone, suggestive of a 
regulatory role for vitamin D 56.  Splice variants found in UGT2A1/2 that are highly 
conserved among both UGT1A and UGT2 gene families have been implicated in altered 
glucuronidation activity against tobacco carcinogenesis 49, 53, 55, 57.  Two of the UGT2A1 
SNPs associated with EOC and HGSOC in this study are intron variants (rs10017134 
and rs2288741) while the third (rs11939884) is a 3’ UTR variant.  It is probable that 
these variants alter enzyme function in target tissues including ovarian and/or alter risk 
in AA smokers. Of note, cigarette smoking has been found to be associated with the 
risk of mucinous EOC, but not HGSOC among Caucasion women 58. Moreover, 
providing some plausibility for the mechanism of the observed SNP association, a 
recent report suggests that cigarette smoking may be associated with serous EOC 
among African American women although a dose-response relationship was not 
observed 59.  The association of genes from the UGT superfamily with ovarian cancer 
in AA is consistent with significant associations observed for Caucasian women for 
UGT1A12.  However in that study, no association was observed for AA samples which 
had a MAF of 0.42 for the risk allele while Caucasians had MAF of 0.07.  Some but not 
all MAFs for the relationships observed in this study differ by race so it is unlikely to 
explain racial differences in race.  
 The EGFR gene product has been a chemotherapeutic target for EOC since 
overexpression has been linked to poor prognosis in ovarian cancer patients 60-62. The 
signaling pathway for EGFR is mediated by ligands including the epidermal growth 
factor in the regulation of cell proliferation, differentiation and apoptosis in normal cells.  
Research into the mechanisms of EGFR overexpression has focused on mutations and 
amplifications in the coding region of the gene containing the receptor tyrosine kinase 
domain 63. However, few studies on SNP variants in this region have been linked to 
EOC or other ovarian cancer histologic subtypes 61, 63.  EGFR SNP rs114972508 is 
located in intron 1 of the EGFR gene. The location of the SNP is approximately 70 kb 
upstream of a VDR binding site also within EGFR intron 1 that has been shown 
experimentally to down regulate EGFR expression and proliferative function 15.  
Perhaps changes in the intron sequences may impact EGFR function and subsequently 
be as critical to cellular homeostasis as the receptor tyrosine function that has been 
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extensively researched. Thus, EGFR SNPs could be abrogating vitamin D hormone 
regulation of ovarian cell proliferation and increasing susceptibility for the development 
of HGSOC in AA women.  
 Although we were unable to confirm the association between previously 
identified VDR variants and risk of EOC, a recent case-control study of women of 
European ancestry (10,065 cases, 21,654 controls) showed that SNPs associated with 
decreased circulating 25-hydroxyvitamin D were associated with ovarian cancer and 
HGSOC 64 while another study showed that AA women exposed to increased sunlight 
had a decreased risk for ovarian cancer 8. These observations suggest that other 
mechanisms affecting vitamin D hormone activity independent of the VDR may be 
important in ovarian cancer etiology.  
The main observations in the current study result from imputations of genotyped 
SNPs but independent of VDR  variant association with EOC and HGSOC. The VDR 
SNPs previously observed to be associated with the risk of EOC 11, including rs7975232 
and rs7305032, were not associated with risk of EOC in the current study 
(Supplemental table 7).  A look up of the significant study SNPs in archived OCAC data 
on Caucacians shows no significant associations for the UGT2A1/2 SNPs. Data on the 
EGFR SNP was not available (Supplemental Table 8).  Other VDR SNPs showed 
nominal (non-Bonferroni corrected) associations with EOC but not with HGSOC 
(Supplemental Table 7). Although the largest study to date of genetic association with 
EOC in AA, the modest sample size remains a limitation of the current study and 
therefore some of the nominal SNP associations may be a result of inadequate power. 
The analyses are underpowered for discovery analysis across the selected gene 
regions and important associations may have been missed, nonetheless, we still found 
significantly associations with EOC and HGSOC. Several suggestive and nominal SNP 
associations (outside of Bonferroni significance) may provide some insight and 
consideration for future experimental studies to further explore the relevance of vitamin 
D biosynthesis and pathway target genes. Larger studies of AA are warranted to clarify 
these finding. 
In summary, this study reports, for the first time, an association between EGFR 
and UGT2A1/2 variants with ovarian cancer risk in AA women. These gene variants 
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could perturb cell proliferation and enzyme efficacy in ovaries and impact susceptibility 
to ovarian cancer by altering growth and intercellular hormone metabolism.  Future 
studies are needed to validate the associations of the imputed SNPs and to determine 
their impact on cancer development.  Currently, there are no published reports of 
population studies of UGT2A1/2 polymorphisms in Europeans or other racially distinct 
groups in larger sample sizes than this AA study that would allow intricate gene-
environment analysis. At this present time, there is only speculative evidence that 
UGT2B gene region variants may be associated with differences in nicotine metabolism 
across African American, Native Hawaiian, Caucasian, Latino, and Japanese American 
smokers 65, 66.  Analyses of the UGT2A1/2 variants across populations may reveal 
differential risk to ovarian disease. In addition, expression and functional analysis in 
ovarian tissue needs to be accomplished to elucidate the impact on tissue homeostasis.  
In spite of the limitations of this study, these results provide new insight into proliferative 
and hormone target pathways that may represent important opportunities for the 
development of chemotherapeutic targets and intervention strategies.    
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Table 1.  Top  SNP  P-values from gene regions associated with EOC in African American OncoArray analysis 
SNP ID 
(Effect / other allele) 
Nearest gene(s) 
Effect 
Allele 
Frequency 
N OR 95% CI P-value 
Bayesian 
False 
Discovery 
Probability 
(BFDP) 
Imputation 
quality 
rs10017134 (C/T) UGT2A1/2a* 0.73 1990 1.4 (1.2, 1.7) 1.2 x 10-6 0.020 0.998 
rs2288741 (T/G) UGT2A1/2* 0.73 1990 1.4 (1.2, 1.6) 1.9 x 10-6 ------- ------- 
rs11939884 (T/G) UGT2A1/2a* 0.14 1990 0.7 (0.5, 0.8) 1.7 x 10-6 ------- ------- 
a
Imputed 
*Bonferroni correction was applied to adjust for multiple SNPs comparisons. There were 433 SNPs in UGT2A1/2 gene. BFDP is 
reported based on a prior probability of association (pi0) equal to 0.6 * 1/(Number of SNPs / 3). 
 
 
 
Table 2.  Top  SNP  P-values from gene regions associated with HGSOC in African American OncoArray analysis 
SNP ID 
(Effect / other allele) 
Nearest gene(s) 
Effect Allele 
Frequency 
N OR 95% CI P-value 
Bayesian 
False 
Discovery 
Probability 
(BFDP) 
Imputation 
quality 
rs114972508 (T/C) EGFRa* 0.04 1772 2.3 (1.2, 3.4) 1.6 x 10-5 0.293 0.890 
rs10017134 (C/T) UGT2A1/2a+ 0.72 1772 1.4 (1.2, 1.7) 2.3 x 10-5 0.228 0.998 
rs2288741 (T/G) UGT2A1/2+ 0.72 1772 1.4 (1.2, 1.7) 3.1 x 10-5 -------- ------- 
a
Imputed 
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*Bonferroni correction was applied to adjust for multiple SNPs comparisons. There were 824 SNPs in EGFR gene, and 413 SNPs 
in UGT2A1/2 gene. BFDP is reported based on a prior probability of association (pi0) equal to 0.5 * 1/(Number of SNPs / 3). 
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